Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable Completed Phase 2 Trials for Alemtuzumab (DB00087)

IndicationStatusPhase
DBCOND0029236 (Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00040846Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological MalignanciesTreatment